Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Patient plan: look up a medication list

MIRTAZAPINE

All products: general benefit

Other products in the same Health Canada class (N06AX) — coverage varies; not interchangeable

  • Duloxetine (Cymbalta): general benefit, Not a benefit
  • Trazodone (Desyrel): general benefit, Not a benefit
  • Venlafaxine (Effexor XR): general benefit
  • Vortioxetine (Trintellix): general benefit
  • Bupropion (Wellbutrin XL): limited Use 315, Not a benefit
  • Desvenlafaxine (Pristiq): not a benefit

17 more in the class list below

Remeron · DIN 02243910 · 30mg · tablet

General benefitMarketed · checked 2026-09-02
StatusGeneral benefit
Write on scriptno code needed
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
1 brand, same coverage
Remeron · DIN 02243910 Manufacturer: Organon Canada Inc.; listing date 2002-07-29 Health Canada: Marketed since 2022-05-17 · brand REMERON · ATC N06AX11 MIRTAZAPINE · form Tablet · route Oral · ingredients MIRTAZAPINE 30 MG · company Organon canada inc. · schedule Prescription
Check this DIN again · Health Canada product record

Ministry pays: $0.3100 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852 · Verify on the e-Formulary ↗ (DIN 02243910)

Source record
DIN 02243910: Remeron Raw flags: sec3=Y Item: 281604107; group id 464; item number 1168; lccId None; manufacturer id OCI Source form: Tab; strength: 30mg Recorded listing: General benefit Source prices (unrounded): $1.8987; ministry $0.3100 Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02243910 Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=67852
Interchangeable products
Apo-Mirtazapine · DIN 02286629 · $0.3100 Auro-Mirtazapine · DIN 02411709 · $0.3100 Mirtazapine · DIN 02370689 · $0.3100 Mirtazapine · DIN 02496674 · $0.3100 Mylan-Mirtazapine · DIN 02256118 · $0.3100 NRA-Mirtazapine · DIN 02534932 · $0.3100 PMS-Mirtazapine · DIN 02248762 · $0.3100 Sandoz Mirtazapine · DIN 02250608 · $0.3100 Teva-Mirtazapine · DIN 02259354 · $0.3100
Shortage status: resolved shortage (ended 2019-01-11); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02243910
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Other drugs in the same formulary class (28:16:04 Antidepressants) and how they are covered

Matched class: 28:16:04 Antidepressants

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: AMITRIPTYLINE, CLOMIPRAMINE HCL, FLUVOXAMINE MALEATE, NORTRIPTYLINE, PHENELZINE SULFATE, SERTRALINE HCL, TRANYLCYPROMINE SULFATE, VENLAFAXINE HCL, VORTIOXETINE HYDROBROMIDE Some products covered without a code (check the product listing): CITALOPRAM HYDROBROMIDE, DESIPRAMINE, DOXEPIN HCL, DULOXETINE, ESCITALOPRAM, FLUOXETINE HCL, IMIPRAMINE, MOCLOBEMIDE, PAROXETINE HCL, TRAZODONE HYDROCHLORIDE, TRIMIPRAMINE 28:16:04 Antidepressants

DULOXETINE

· 38 products · Listed, not a benefit (2), General benefit (36) · strengths: 30mg, 60mg · DR Cap

TRAZODONE HYDROCHLORIDE

· 17 products · Listed, not a benefit (3), General benefit (14) · strengths: 50mg, 100mg, 150mg · Tab

VENLAFAXINE HCL

· 45 products · General benefit · strengths: 37.5mg, 75mg, 150mg · ER Cap

VORTIOXETINE HYDROBROMIDE

· 6 products · General benefit · strengths: 5mg, 10mg, 20mg · Tab

BUPROPION HCL

· 12 products · Limited Use, codes 315 (10), Listed, not a benefit (2) · strengths: 150mg, 300mg, 100mg · ER Tab, Tab

DESVENLAFAXINE

· 18 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 50mg, 100mg · ER Tab

VILAZODONE HYDROCHLORIDE

· 6 products · Off-Formulary Interchangeable, not an ODB benefit · strengths: 10mg, 20mg, 40mg · Tab

AMITRIPTYLINE

· 12 products · General benefit · strengths: 10mg, 25mg, 50mg · Tab

CITALOPRAM HYDROBROMIDE

· 51 products · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) · strengths: 10mg, 20mg, 40mg · Tab

CLOMIPRAMINE HCL

· 5 products · General benefit · strengths: 25mg, 50mg, 10mg · Tab

DESIPRAMINE

· 7 products · Listed, not a benefit (4), General benefit (3) · strengths: 25mg, 50mg, 75mg · Tab

DOXEPIN HCL

· 20 products · General benefit (12), Off-Formulary Interchangeable, not an ODB benefit (8) · strengths: 10mg, 25mg, 50mg, 75mg, 100mg · Cap Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26; class 28:16:04 and 12 more
Full class listing Related classes: 28:08:04 Nonsteroidal Anti-Inflammatory Agents, 28:08:08 Opiate Agonists, 28:08:12 Opiate Partial Agonists, 28:08:92 Miscellaneous Analgesics and Antipyretics, 28:16:08 Tranquilizers, 28:16:12 Other Psychotropics, 28:36:08 Anticholinergic Agents, 28:36:20 Dopamine Receptor Agonists Same formulary class, not same indication: class membership alone does not establish equivalent uses.
Other drugs whose Health Canada label lists a similar indication: depressive illness, the symptomatic relief of depressive illness
From Health Canada product monographs; label wording only, not a treatment recommendation. Matching is lexical and uses one held product label per generic; formulations and qualifying criteria may differ. Covered without a code on the Ontario formulary: AMITRIPTYLINE, SERTRALINE HCL CITALOPRAM HYDROBROMIDE · Off-Formulary Interchangeable, not an ODB benefit (9), General benefit (42) Indications CELEXA (citalopram hydrobromide) is indicated for: • the symptomatic relief of depressive illness in adults The relapse rate was significantly lower in CELEXA-treated patients than in placebo-treated patients in two placebo-controlled studies that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with CELEXA (see 14.1 Clinical Trials by Indication). PM: https://pdf.hres.ca/dpd_pm/00082636.PDF; date not captured; DIN 02239607; fetched 2026-09-10 Product monograph • the symptomatic relief of depressive illness in adults The relapse rate was significantly lower in CELEXA-treated patients than in placebo-treated patients in two placebo-controlled studies that were conducted over a 24-week period in patients who responded to 6 or 8 weeks of acute treatment with CELEXA (see 14.1 Clinical Trials by Indication). Nevertheless, the physician who elects to use CELEXA for extended periods should periodically re-evaluate the long- term usefulness of the drug for the individual patient. PM: https://pdf.hres.ca/dpd_pm/00082636.PDF; date not captured; DIN 02239607; fetched 2026-09-10 Product monograph AMITRIPTYLINE · General benefit 1 INDICATIONS pms-AMITRIPTYLINE (amitriptyline hydrochloride) is indicated for: • Drug management of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00074345.PDF; date December 11, 1998; DIN 00654507; fetched 2026-09-10 Product monograph SERTRALINE HCL · General benefit 1 INDICATIONS ZOLOFT (sertraline hydrochloride capsules) is indicated for: Adults  Depression ZOLOFT is indicated for the symptomatic relief of depressive illness. PM: https://pdf.hres.ca/dpd_pm/00072140.PDF; date AUG 22, 2023; DIN 01962779; fetched 2026-09-10 Product monograph Coverage source: ON formulary extract 2026-08-26
What the Health Canada label says it is for
1 INDICATIONS REMERON® (mirtazapine) is indicated for: • the symptomatic relief of depressive illness. Long-term use of REMERON® The efficacy of REMERON® in maintaining a response in patients with major depressive disorder for up to 40 weeks following 8 - 12 weeks of initial open-label treatment was demonstrated in a placebo-controlled trial. Nevertheless, the physician who elects to use REMERON® for extended periods should periodically evaluate the long-term response of the individual patient to the drug. 1.1 Pediatrics Pediatrics (< 18 years of age): REMERON® is not indicated for use in patients below the age of 18 years (see WARNINGS AND PRECAUTIONS, General, Potential Association with Behavioural and Emotional Changes, Including Self-Harm; see also ADVERSE REACTIONS/Pediatrics, DOSAGE AND ADMINISTRATION and ACTION AND CLINICAL PHARMACOLOGY Special Populations and Conditions/Pediatrics). 1.2 Geriatrics Geriatrics (> 65 years of age): Evidence from clinical trials and experience suggests that use in geriatric populations may be associated with differences in safety or effectiveness. A brief discussion can be found in the appropriate sections [see WARNINGS AND PR… https://pdf.hres.ca/dpd_pm/00075141.PDF PM date: May 4, 2021 Source product: REMERON; DIN 02243910; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.